Cerenis Therapeutics News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

13.06.24	ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis (Businesswire)
15.02.24	ABIONYX Pharma Acknowledges the Clinical Results of the Phase 3 AEGIS-II Study Evaluating the Efficacy and Safety of CSL Behring’s Human-plasma-derived apoA-I, CSL112 (Businesswire)
02.11.23	ABIONYX Pharma RACERS Study Data in Sepsis Presented at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week" (Businesswire)
16.10.23	ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology (ASN) 2023 Annual Meeting "Kidney Week" (Businesswire)
31.03.23	ABIONYX Pharma Announces Its Strategy in Ophthalmology and New Positive Preclinical Results for the Deployment of Two Innovative Technology Platforms: Apotherapy and Biovectorization (Businesswire)
16.01.23	ABIONYX Pharma Reports Positive Results from Phase 2a Pilot Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury (Businesswire)
07.04.22	ABIONYX Pharma Reports Positive Interim Results From Phase 2a Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury (Businesswire)
29.03.22	ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease (Businesswire)
24.03.22	ABIONYX Announces Positive Clinical Findings for CER-001 in Treating COVID-19, Published in Biomedecines, Demonstrating That CER-001 Limits Inflammation Effects (Businesswire)
02.03.21	ABIONYX Announces Positive Clinical Results From CER-001 in the LCAT Deficiency Disease Published in the Annals of Internal Medicine (Businesswire)
22.10.18	CERENIS to Present New Data Validating HDL Targeted Drug Delivery in the Field of Oncology and Immuno-Oncology at the 30th EORTC/NCI/AACR1 Symposium (Businesswire)
31.07.18	Cerenis Announces Today the Appointment of Barbara Yanni to Its Board of Directors as an Independent Director (Businesswire)
26.07.18	Cerenis Announces Financing from Investment Funds, Management, Its Board of Directors and Its Oncology Scientific Advisory Board (Businesswire)
25.06.18	Cerenis Therapeutics: First results of TARGET PHASE II study demonstrate the ability of CER-001, an HDL mimetic, to target tumor in patients with esophageal cancer (Businesswire)
07.05.18	Cerenis to Attend 2018 HDL Workshop (adjacent to ATVB\|PVD Scientific Sessions) (Businesswire)
02.05.18	Seasoned Scientific Experts and Strategic Pharmaceutical Industry Veterans Join Cerenis’ Scientific Advisory Board in Oncology (Businesswire)
12.02.18	Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
01.02.18	CERENIS Therapeutics: 2017 Annual Results and Update on TANGO (Businesswire)
25.01.18	CERENIS Therapeutics: Cash Position and Activity Update for Q4 2017 (Businesswire)
23.01.18	Cerenis Therapeutics: 2018 Financial Agenda (Businesswire)
05.01.18	Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
04.12.17	Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
22.11.17	First Patients Enter TARGET Study, Recently Initiated by Cerenis Therapeutics to Evaluate HDL Nanoparticles in Patients with Esophageal Cancer (Businesswire)
14.11.17	Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
08.11.17	CERENIS Therapeutics Acquires LYPRO Biosciences Expanding Its HDL Strategy Into Immuno-Oncology and Chemotherapeutic Drug Delivery (Businesswire)
26.10.17	Cerenis Therapeutics: Cash Position and Activity Update for Q3 2017 (Businesswire)
18.10.17	Cerenis Therapeutics: Completion of Patient Enrollment in the Phase 3 Study, TANGO, Evaluating CER-001 in HDL Genetic Deficiency (Businesswire)
12.09.17	Cerenis Therapeutics: 2017 Half-Year Results (Businesswire)
04.09.17	Cerenis Therapeutics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City, September 10-12, 201 (Businesswire)
02.08.17	Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
20.07.17	Cerenis Therapeutics: Cash Position and Activity Update for H1 2017 (Businesswire)
03.05.17	Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
28.04.17	Cerenis Therapeutics: Publication of 2016 Registration Document (Businesswire)
20.04.17	Cerenis Therapeutics: Cash Position and Update on Clinical Developments for Q1 2017 (Businesswire)
18.04.17	Cerenis Therapeutics Announces the Initiation of the Phase 1 Clinical Study with CER-209 in NAFLD and NASH (Businesswire)
02.03.17	Cerenis Therapeutics: Monthly statement of total voting rights and shares forming the company’s share capital (Businesswire)
12.01.17	Cerenis Therapeutics: Monthly statement of total voting rights and shares forming the company’s share capital (Businesswire)
15.12.16	Cerenis Therapeutics Receives FDA IND Approval to Begin Studies with CER-209 in NAFLD and NASH (Businesswire)
08.11.16	Cerenis Therapeutics Announces Last Patient Dosed in CARAT Phase II Study with CER-001 in Post-Acute Coronary Syndrome Patients (Businesswire)
07.11.16	Cerenis Therapeutics: Cash Position and Revenue for Q3 2016 (Businesswire)
06.10.16	Cerenis Therapeutics: Monthly statement of total voting rights and shares forming the company’s share capital (Businesswire)
05.09.16	Cerenis Therapeutics: 2016 Half-Year Results (Businesswire)
01.09.16	Cerenis Therapeutics: Monthly Statement of Total Voting Rights and Shares Forming the Company’s Share Capital (Businesswire)
01.09.16	Positive Safety and Tolerability Profile of CER-001 Presented at the European Society of Cardiology (ESC) Congress 2016 (Businesswire)
30.08.16	Cerenis Therapeutics: Completion of Patient Enrolment in the CARAT Study – Meeting the Clinical Schedule (Businesswire)
28.07.16	Cerenis Therapeutics: Cash Position and Revenue for the 1st Semester of 2016 (Businesswire)
02.06.16	Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS) (Businesswire)
02.06.16	Cerenis Therapeutics: Publication of the LOCATION Clinical Study Results in the Renowned Scientific Journal of the European Atherosclerosis Society (EAS) (Businesswire)
03.05.16	Cerenis Therapeutics: Cash Position and Revenue for the 1st Quarter of 2016 (Businesswire)
18.04.16	Cerenis Therapeutics Announces the Publication of an Initiation of Coverage Report by PORTZAMPARC, within the Framework of the Share’s Market Coverage (Businesswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V